DTYMK

deoxythymidylate kinase

Explore in graph →CI-GENE-00043947HGNC:3061 ENSG00000168393 NCBI 1841 CIViC Approved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
DTYMK Decreased RNA expression1
Fluorouracil	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID13314 shRNA-mediated DTYMK knockdown increased fluorouracil sensitivity, decreasing IC50 approximately threefold in HT-29 cells and fivefold in HCT-116 cells. PMID 21449674 · Muhale et al., 2011 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (1)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved1 cohort row · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018) all_phase2_target_2018_pub	B Lymphoblastic Leukemia/Lymphoma	Ssm	1	150	0.7%

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.